Efficacy News and Research

RSS

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Moberg Derma AB has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011

N.J. plans to use managed care system for Medicaid enrollees with mental health problems

The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.

15 Nov 2011

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.

15 Nov 2011

New clues about connections among fat, inflammation and insulin resistance

In a new study, scientists report that they substantially curbed weight gain, improved metabolism, and improved the efficacy of insulin in mice by engineering them to express a specific human enzyme in their fat tissue. Although the obesity prevention came at the significant cost of widespread inflammation, the research offers new clues about the connections among obesity, insulin resistance and type 2 diabetes, and inflammation.

14 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Demand for non-drug intervention for atrial fibrillation will remain, despite FDA PVAC decision

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the search for an improved method of treating atrial fibrillation (AF) will be unaffected by the recent mixed decision by the Food and Drug Administration (FDA) panel on Medtronic's phased radiofrequency (RF) pulmonary vein ablation catheter (PVAC).

From Medtronic 14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

Health supplement hope for child muscle disease

A health supplement used by bodybuilders could be the key to treating a life-threatening muscular dystrophy affecting hundreds of Australian children, new research shows.

14 Nov 2011

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.

11 Nov 2011

YM BioSciences reports revenue of $0.3 million for first quarter 2012

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today reported operational and financial results for its first quarter of fiscal 2012, ended September 30, 2011.

11 Nov 2011

Conference highlights advances in evidence-based integrative therapies for cancer

Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio. More than 80 abstracts will be presented at the annual meeting, which will be keynoted by National Institutes of Health Director, Francis Collins, MD, PhD.

11 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

FDA licenses NYBC's HEMACORD stem cell product

The Food and Drug Administration has licensed HEMACORD for allogeneic hematopoietic (blood-forming) stem cell transplantation, the first such approval of a stem cell product in the world.

11 Nov 2011

Efficacy News and Research

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

N.J. plans to use managed care system for Medicaid enrollees with mental health problems

Mesoblast reports positive Revascor Phase 2 heart failure trial results

New clues about connections among fat, inflammation and insulin resistance

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Demand for non-drug intervention for atrial fibrillation will remain, despite FDA PVAC decision

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Health supplement hope for child muscle disease

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

IVI receives WHO prequalification for new oral cholera vaccine

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

YM BioSciences reports revenue of $0.3 million for first quarter 2012

Conference highlights advances in evidence-based integrative therapies for cancer

Ampion safe and effective for patients with nasal inflammation

FDA licenses NYBC's HEMACORD stem cell product

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News